Sat Kartar Shopping

Sat Kartar Shopping

CLOSED

IPO Date: 10 Jan - 14 Jan 2025

Listing Date: 17 Jan 2025

Price Range

₹77 – ₹81

Issue Size

34 Cr

Min Investment

1,23,200

Lot Size

1600 Shares

Schedule of Sat Kartar Shopping

Issue open date

10 Jan 2025

Issue close date

14 Jan 2025

UPI mandate deadline

14 Jan 2025 (5 PM)

Allotment finalization

15 Jan 2025

Share credit

16 Jan 2025

Listing date

17 Jan 2025

Mandate end date

29 Jan 2025

Issue size

Funds Raised in the IPOAmount
Overall34 Cr
Fresh Issue33.8 Cr
Offer for Sale0 Cr

Allotment DetailsNew

Allotment TimelineDetails
Allotment Date15 Jan 2025
Allotment Link{Link}

Grey Market PremiumNew

Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.

DateIpo PriceGMPEstimated Listing Price
17 Jan 20258140121 (49.38%)
16 Jan 20258140121 (49.38%)
15 Jan 20258149130 (61%)
14 Jan 20258160141 (74%)
13 Jan 20258130111 (37%)
11 Jan 20258132113 (40%)
10 Jan 20258132113 (40%)
9 Jan 20258124105 (30%)
8 Jan 2025811091 (12%)

Performance Sat Kartar Shopping

Issue PriceListing GainCurrent Market PriceP/L
₹77 – ₹81 160 (99.44%) 147.582.10%

About Sat Kartar Shopping

Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company offering natural wellness solutions. The company specializes in therapeutic and lifestyle products based on traditional Ayurveda practices, targeting areas such as addiction, diabetes, joint pain, and mental wellness. It sells its products directly to consumers through its website, third-party e-commerce platforms, TV marketing, and digital channels. They operate with contract manufacturers for production, focusing on product development and distribution.

Founded in2012
Managing directorMr. Ved Prakash
Parent organizationSat Kartar Shopping Ltd

Financial Overview

Strengths

  • PAN India revenue, key cities: Tamil Nadu, Uttar Pradesh, Karnataka
  • Asset-light, focused on marketing and customer satisfaction
  • In-house R&D by BAMS doctors for product formulations
  • Clinical trials published in the World Journal of Pharmaceuticals Research
  • Efficient logistics with climate-controlled warehouses for timely deliveries

Risks

  • Consumer complaints and litigation may impact business
  • Brand image issues could hinder growth
  • Dependence on third-party manufacturers risks quality and supply
  • Revenue heavily reliant on top 5 states; adverse changes could affect growth
  • Risk of manufacturers claiming formulation ownership
  • Counterfeits could damage reputation and financials

Subscription Figures

CategorySubscription (No. of times)
Qualified Institutional Buyers (QIBs)124
Non-Institutional Investors (NIIs)808
Retail Individual Investors (RIIs)250
EmployeeN/A
Total332